This is a preview of subscription content, log in via an institution to check access.
References
Allaway GP, Davis-Bruno KL, Beaudry GA, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995 May; 11: 533–9
Israel R, Jurcic J, Sgouros G, et al. Aphase I trial of 131I-CD4-gamma-2 (recombinant human CD4-IgG2 fusion protein) in HIV-1 infected patients. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 2; Washington, 117
Progenics reports progress in lead cancer and HIV programs — promising results presented at two international scientific conferences [press release]. Progenics Pharmaceuticals Inc. 1998 Jun 22
Progenics identifies novel HIV product and presents Pro 542 clinical results [press release]. Progenics Pharmaceuticals Inc. 1998 Feb 3
Rights and permissions
About this article
Cite this article
PRO 542. Drugs R&D 2, 350–351 (1999). https://doi.org/10.2165/00126839-199902050-00017
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902050-00017